Title: Gestational exposure of mice to environmentally persistent free radicals leads to increased weight gain in offspring.

Short Title: Gestational EPFR Exposure and Weight Gain

Authors:

Dave Bridges1,2,3, Alyse Ragauskas1,2, Erin Stephenson1,2, Sridhar Jaligama2, Jyothi Parvathareddy2, Kathryn Cyrus1,2 and Matthew J. Peloquin1,2 and Stephania A. Cormier2,3

Addresses:

1Department of Physiology, University of Tennessee Health Science Center, Memphis TN. 2Department of Pediatrics, University of Tennsessee Health Science Center, Memphis TN

3Corresponding authors

[dbridge9@uthsc.edu](mailto:dbridge9@uthsc.edu) and [scormier@uthsc.edu](mailto:scormier@uthsc.edu)

# Abstract

# Introduction

# Methods and Materials

## MCP230 Preparation and Treatment

Steph can you write this section

## Animal Housing and High Fat Diet

Mice were maintained in a 12h light/dark cycle room at constant temperature and humidity and allowed unrestricted access to food and water. At 10 weeks of age, mice were switched from chow to a high fat diet, consisting of 45% of calories from fat (Research Diets catalog D12451). One mouse, a MCP230 treated animal had a malocclusion and was removed from our analyses. The UTHSC Institutional Animal Care and Use Committee approved all mouse procedures.

## Metabolite Assays and Liver Triglyceride Determination

Liver triglycerides were determined as previously described [1]. Briefly, liver tissue was homogenized in XXX, then extracted with a 2:1 chloroform:methanol solution. The lipid phase was then removed, dried and resuspended. Triglycerides were measured using a colorimetric assay (Sigma-Aldrich, catalog TR0100). Glucose was determined using an Accucheck glucometer. Serum hormone levels were determined using a BioRad multiplex analyte assay (catalog , following the manufacturer’s instructions.

## Body Composition and Metabolic Cages

Mice were weighed weekly at approximately ZT10. Body composition was determined non-invasively using an echo-MRI 100 at approximately ZT10. Food intake during the HFD phase was determined on a per-cage level by weighing the food on a weekly basis. For pre-HFD food intake, this was the sum of food eaten during the time in the metabolic cages, as determined by scaled feeder.

Energy expenditure, ambulatory locomotor activity and respiratory exchange ratios were determined in a home-cage style comprehensive laboratory animal monitoring system (Columbus Instruments). Mice were placed in the cages at approximately ZT10 and monitored for 3-4 days. Data from the first 6h were discarded as this was the approximate amount of time for the mice to become accustomed to their new single-caged environment. The Oxymax software provided by the vendor calculated the volumes of O2, CO2, the respiratory exchange ratio, the ambulatory x-phase physical activity and the food consumption.

## Statistics

Statistics and calculations were performed using Microsoft Excel and R version 3.1.1 [2]. For longitudinal data, mixed linear models were used and χ2 tests were performed to determine the significance of the MCP230 treatment. Mixed linear models used the R package lme4 (version 1.1-7 [3]). In all cases, normality of the data and models were determined via Shapiro-Wilk Test and equal variance was tested using Levene’s test from the car package (version 2.0-21 [4]). In cases where cabosil and saline treatment were not significantly different, these data were combined and designated as “Control”. For energy expenditure calculations, we performed an ANCOVA analysis with lean body mass and the treatment group as non-interacting covariates and the averaged light or dark VO2 as the responding variable as described in [5]. Statistical significance was designated as a p-value <0.05.

# Results

## Gestational exposure to MCP230 leads to increased weight gain in pups

To test whether gestational exposure to an environmentally persistent free radical, we treated pregnant females with two exposures of MCP230 on gestational day 10 and 17. These mice were then birthed, left with their dams and weaned at 21 days of age. At 10 weeks of age, mice were placed on a high fat diet consisting of 45% of calories from fat (see Figure 1A).

As shown in Figure 1B, mice that were pre-treated with MCP230 started at a higher body weight and proceeded to gain more weight during the diet. At the end of the 12-week diet, we observed a XXg (XX%) increase in body size (Figure 1B). We assessed the body composition and observed significant elevations in both fat mass (10.6% increase, p=0.011) and lean mass (10.8% increase, p=2.2x10-4) in these mice (Figures 1C and D). The relative adiposity of these mice as determined by the percent fat mass was unchanged (Figure 1E).

We next evaluated the extent of obesity related co-morbidities in these mice. As shown in Figure 2A, hepatic steatosis was elevated by high fat diet to an equal extent in both groups of mice. We also examined no changes in blood glucose (Figure 2B). As shown in Figure 2C, we also did not observe any changes in hyerinsulinemia, suggesting no alterations in insulin sensitivity between the saline and MCP230 treated mice after high fat diet.

To test whether there were any other changes in key metabolic hormone levels, we evaluated the levels of a panel of these from fasted mice. As shown in Figures 2E-F, we did not observe any changes in resistin or PAI-1 levels. Leptin was modestly elevated in both the fasted and fed conditions (p-value for the effect of MCP230 treatment via ANOVA was 0.011, post-hoc *t-*test p-values were 0.058 for fasted and p=0.097 for fed leptin levels). These elevations in circulating leptin levels are consistent with the increases in fat mass described in Figure 1E. We observed significant elevations in both the fasting and fed state for Ghrelin, GLP-1, glucagon and GIP-1, though the latter did not quite reach statistical significance (p=0.069 for fasted GIP-1 levels by Wilcoxon Rank Sum Test).

## MCP230 Mice Have Reduced Caloric Intake

To determine how energy balance was affected in these mice we first examined their food intake, longitudinally throughout the study. As shown in Figure 3A, the mice tended to eat lower amounts of food each week, though this did not reach statistical significance. Cumulatively, the MCP230 ate less food throughout the diet (-6.3 +/- 1.8 kcal/week/mouse, χ2=11.6, p=8.0 x 10-4, Figure 3B). Through the 12 week high fat diet treatment this corresponds to a 20% reduction in total caloric intake. To determine whether this reduction in food intake occurred at baseline, or only was due to the HFD, we also examined mice, individually housed at 10 weeks of age. These mice also consumed less food. Together these data suggest that the larger, particulate treated mice did not gain more weight due to caloric intake, and in fact had substantially less calories consumed.

## MCP230 Mice Have Reduced Energy Expenditure

Since the MCP230 mice did not appear larger due to excessive caloric intake, we next examined their energy utilization. To evaluate energy expenditure, we placed mice at 9 weeks of age (prior to HFD) in individual cages for indirect calorimetry, physical activity monitoring and evaluation of gas exchange rates.

As shown in Figure 3C, the MCP230 treated mice had lower energy expenditure as determined by indirect calorimetry. Figure 3D describes the energy expenditure, as determined by the volume of O2 consumed for each mouse, plotted against the animal’s lean body mass. Accounting for change in lean body mass is necessary due to known associations between this covariate and oxygen consumption rates [5]. Based on these calculations, we observed decreased energy expenditure of the MCP230 treated mice in both the dark (-19.1%, p=0.020) and light (-16.8%, p=0.031) phases.

To determine whether these decreases in energy expenditure were correlated with changes in locomotor activity, we simultaneously monitored ambulatory activity of these mice. As shown in Figure 3E, we observed a 21.4% reduction in activity in the dark phase (p=0.040) and a 26.2% decrease in light phase locomotor activity (p=0.0099).

## Muscles from MCP230 Treated Mice Have Reduced Mitochondrial Content

# Discussion

In this study we have tested the effects of a limited gestational exposure to a environmentally persistent free radical associated with particulate matter as a mimic of combustion derived pollutants. We have noted that these mice grew larger in spite of reductions in food intake, likely due to reduced energy expenditure and mitochondrial number.

The appetite stimulating hormone ghrelin is typically elevated with fasting (See Figure 2G; [6, 7]). In the context of reduced observed food intake, it is likely that the elevated ghrelin levels in the MCP230 are a response to reduced food intake. This potential counter-regulatory mechanism is consistent with observations that ghrelin levels are reduced with obesity [8–10]. Elevations in GLP-1 on the other hand inhibits food intake [11, 12], so these changes could potentially play a role in the reduced appetite of the MCP230 treated mice.

One potential explanation for the reductions in energy expenditure is that this is driven by reduced locomotor activity. On the other hand, it is possible that muscle weakness due to reduced mitochondrial capacity is the driver of the reduced physical movement in these animals.

# Acknowledgements

We would like to acknowledge funding from Le Bonheur Grant #650700 (DB) and XXXX. The authors would like to thank Jordy Saravia for assistance with the luminex assay and the other members of the Bridges and Cormier labs for helpful discussions and insights.

# References

1. Lu, B., Bridges, D., Yang, Y., Fisher, K., Cheng, A., Chang, L., Meng, Z., Lin, J. D., Downes, M., Yu, R. T., et al. (2014). Metabolic crosstalk: molecular links between glycogen and lipid metabolism in obesity. Diabetes *63*, 2935–48.

2. R Core Team (2013). R: A Language and Environment for Statistical Computing.

3. Bates, D., Mächler, M., Bolker, B., and Walker, S. (2014). Fitting Linear Mixed-Effects Models using lme4. ArXiv *1406.5823*, 1–51.

4. Fox, J., and Weisberg, S. (2011). An {R} Companion to Applied Regression Second. (Thousand Oaks {CA}: Sage).

5. Tschöp, M. H., Speakman, J. R., Arch, J. R. S., Auwerx, J., Brüning, J. C., Chan, L., Eckel, R. H., Farese, R. V, Galgani, J. E., Hambly, C., et al. (2011). A guide to analysis of mouse energy metabolism. Nat. Methods *9*, 57–63.

6. Tschöp, M., Smiley, D. L., and Heiman, M. L. (2000). Ghrelin induces adiposity in rodents. Nature *407*, 908–13.

7. Toshinai, K., Mondal, M. S., Nakazato, M., Date, Y., Murakami, N., Kojima, M., Kangawa, K., and Matsukura, S. (2001). Upregulation of Ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem. Biophys. Res. Commun. *281*, 1220–5.

8. Tschöp, M., Weyer, C., Tataranni, P. a, Devanarayan, V., Ravussin, E., and Heiman, M. L. (2001). Circulating ghrelin levels are decreased in human obesity. Diabetes *50*, 707–9.

9. Peloqiun, M. J., and Bridges, D. (2014). Weight Loss in Response to Food Deprivation Predicts The Extent of Diet Induced Obesity in C57BL/6J Mice.

10. Ikezaki, A., Hosoda, H., Ito, K., Iwama, S., Miura, N., Matsuoka, H., Kondo, C., Kojima, M., Kangawa, K., and Sugihara, S. (2002). Fasting Plasma Ghrelin Levels Are Negatively Correlated With Insulin Resistance and PAI-1, but Not With Leptin, in Obese Children and Adolescents. Diabetes *51*, 3408–3411.

11. Baggio, L. L., Huang, Q., Brown, T. J., and Drucker, D. J. (2004). Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology *127*, 546–558.

12. Turton, M. D., O’Shea, D., Gunn, I., Beak, S. A., Edwards, C. M., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996). A role for glucagon-like peptide-1 in the central regulation of feeding. Nature *379*, 69–72.

# Figure Legends

**Figure 1: Gestationally treatment of MCP230 leads to mice with elevated weight gain on high fat diet.** A) Schematic of treatment. B) Body weight throughout the HFD treatment. C-E) After 12 weeks of HFD, body composition was determined in the fed state (ZT12). Asterisks indicate p<0.05 via a Student’s *t*-test (C-D).

**Figure 2: Gestationally MCP230 treated mice have no changes in liver triglycerides or insulin sensitivity but have elevations in ghrelin.** A) Liver triglycerides and B) blood glucose levels were determined from mice after a 16h fast at approximately ZT4. C-J) Fed (ZT12) and fasted (ZT4) serum hormone levels were determined. Asterisk indicates p<0.05 via a Wilcoxon Rank Sum Test.

**Figure 3: Decreased food intake and energy expenditure in pups from gestationally treated MCP230 mice.** Food intake per mouse was calculated on a A) weekly and B) cumulative basis throughout the High-Fat Diet Treatment. C)